4.9.1.3Vertical

mRNA & Nucleic Acid Therapeutics

Companies developing mRNA, antisense oligonucleotide, siRNA, and other nucleic acid platforms for infectious disease, oncology, rare genetic, and cardiovascular indications.

Market snapshot

These figures describe Biotech & Biopharmaceuticals (4.9.1), the segment that mRNA & Nucleic Acid Therapeutics sits within. They are not figures for mRNA & Nucleic Acid Therapeutics on its own.

Market size
~$211B
Growth
~1.4%CAGR (2017–22, nominal)
Companies
~2,181 firms
Firms by employee count

58.2% of firms have fewer than 20 employees: 1,269 micro-businesses, below most mandates.

The investable universe912 firms with 20+ employees
20–99
40344%
100–499
26829%
500+
24126%

U.S. biopharma manufacturing: ~2,180 firms, extraordinarily asset- and IP-heavy (payroll just 13% of revenue, ~$97M revenue per firm). The ~$211B is U.S. manufacturing receipts; the global, patent-driven market is far larger. Measured growth was slow (~1.4%/yr) because the value sits in IP and pipeline, not domestic production volume. M&A, meanwhile, runs hot, driven by patent cliffs and the GLP-1 boom.

NAICS 325411, 325412, 325414. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census.

Business model & economics

Revenue model

Patent-protected drug sales and royalties

Key economics

Revenue per firm
$96,794,531
Revenue per employee
$804,188
Employees per firm
125.3
Recurring revenue
Moderate

on-patent franchises; cliffs reset it

EBITDA margin
High for branded on-patent drugs
Capex intensity
High

Characteristics

  • Scale-driven: payroll is only 13% of revenue, so the cost base is assets, not headcount
  • Deep strategic-buyer pool: 241 firms exceed 500 employees, so a scaled asset has trade buyers
  • The innovation engine of healthcare: high-risk, R&D-intensive.
  • Patent cliffs drive constant pipeline-replenishing M&A.
  • GLP-1/obesity franchise reshaped sector growth.

NAICS 325411, 325412, 325414. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census.

Geographic concentration

AlabamaAlaskaArizonaColoradoFloridaGeorgiaIndianaKansasMaineMinnesotaNew JerseyNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireNew YorkOhioOregonTennesseeUtahVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoNevadaVermontLouisianaRhode IslandMassachusettsNorth CarolinaCalifornia

Biotech and biopharmaceutical operations concentrate in the established life-sciences clusters of California (the Bay Area and San Diego), Massachusetts (Greater Boston), and North Carolina's Research Triangle. These are by far the largest centers of industry employment.

CaliforniaMassachusettsNorth Carolina

U.S. Census Bureau, 2022 County Business Patterns (employment by state), NAICS 325411/325412/325414. Leading states by biopharmaceutical employment.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Big pharma & biopharma strategics
  • Biotech-acquiring platforms
  • VC- and crossover-backed biotech

What’s driving deals

  • Patent-cliff-driven acquisition of biotech pipelines.
  • GLP-1 and novel-modality competition.
  • Biotech funding cycles and platform deals.

Find mRNA & Nucleic Acid Therapeutics acquisition targets

Search Acquisera’s index for companies classified under mRNA & Nucleic Acid Therapeutics (4.9.1.3) and build a targeted deal pipeline.

Search companies